Author:
Long Georgina V.,Fung Carina,Menzies Alexander M.,Pupo Gulietta M.,Carlino Matteo S.,Hyman Jessica,Shahheydari Hamideh,Tembe Varsha,Thompson John F.,Saw Robyn P.,Howle Julie,Hayward Nicholas K.,Johansson Peter,Scolyer Richard A.,Kefford Richard F.,Rizos Helen
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference60 articles.
1. Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New Engl. J. Med. 367, 1694–1703 (2012).
2. Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. New Engl. J. Med. doi:10.1056/NEJM.a1406037 (2014).
3. Robert, C. et al. COMBI-v: A randomised, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) to vemurafenib (V) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Ann. Oncol. 25, 1–41 (2014).
4. Larkin, J. et al. Combined Vemurafenib and Cobimetinib in BRAF-mutated melanoma. New Engl. J. Med. doi:10.1056/NEJM.a1408868 (2014).
5. Kefford, R. et al. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. ASCO Meet. 31, 9029 (2013).
Cited by
306 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献